Revolution Medicines Cracks KRAS in Pancreatic Cancer at ASCO
For decades, KRAS — the mutation driving most pancreatic cancers — was considered undruggable. Revolution Medicines just reported practice-changing results suggesting that era is over.
Explanation
Pancreatic cancer is one of the deadliest cancers partly because the protein most responsible for it, KRAS, was long thought impossible to block with a drug. Researchers nicknamed it a "greasy ball" — smooth, with no obvious pocket for a drug molecule to grab onto. That's been the wall for 40 years.
At ASCO 2025 (the world's largest oncology conference), Revolution Medicines presented results that appear to clear that wall. Their drug targets KRAS directly, and the results were described as "practice-changing" — a high bar in oncology that means clinicians should now reconsider how they treat patients.
Why does this matter today? Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate under 12%. It's almost always caught late, and existing chemotherapy regimens buy months, not years. A drug that meaningfully targets the root mutation changes the calculus for patients who currently have very few options.
The "greasy ball" framing isn't just colorful — it captures a real structural biology problem that has resisted billions in R&D. The fact that Revolution's molecule appears to work in a clinical setting, not just a lab dish, is the signal worth watching. What to watch next: how durable the responses are, whether resistance emerges fast, and whether this opens the door for combination strategies with existing chemo backbones.
KRAS (Kirsten RAS oncogene) is mutated in roughly 90% of pancreatic ductal adenocarcinomas, making it the defining oncogenic driver of the disease. Its GTPase domain lacks a stable hydrophobic binding groove in its active state — hence the "greasy ball" epithet — which stymied small-molecule inhibition for four decades. Amgen's sotorasib and adagrasib (Mirati) cracked KRAS G12C in lung cancer, but G12C is rare in pancreatic cancer; the dominant variants there are G12D and G12V, which have proven harder to address.
Revolution Medicines' approach — likely a RAS(ON) multi-selective inhibitor based on their disclosed pipeline — targets the active, GTP-bound state of KRAS rather than exploiting the G12C-specific covalent chemistry that unlocked lung cancer. That mechanistic distinction matters: it potentially covers a broader mutant landscape.
The ASCO readout was characterized as "practice-changing," a descriptor the oncology community applies sparingly and which typically implies statistically significant improvement in a clinically meaningful endpoint — overall survival or progression-free survival — over the current standard of care (gemcitabine/nab-paclitaxel or FOLFIRINOX). The source excerpt does not specify the exact endpoint, response rate, or comparator arm, which are critical for full evaluation.
Key open questions: depth and durability of response (KRAS inhibitors in lung cancer show median PFS in the 6–9 month range before resistance), patient selection criteria (all-comers vs. specific KRAS variant), and whether the data are from a randomized controlled trial or a single-arm study. Single-arm data in pancreatic cancer can look impressive against historical controls that don't reflect modern supportive care.
If the responses are durable and the trial is randomized, this is a genuine inflection point — the first molecularly targeted therapy with real traction in a disease that has resisted targeted approaches entirely. Watch for the full data publication and FDA Breakthrough Therapy designation activity.
Reality meter
Why this score?
Trust Layer Revolution Medicines has produced practice-changing clinical results targeting KRAS — the long-undruggable driver mutation — in pancreatic cancer.
Revolution Medicines has produced practice-changing clinical results targeting KRAS — the long-undruggable driver mutation — in pancreatic cancer.
- Results were presented at ASCO, the field's premier clinical oncology conference, lending institutional visibility.
- The drug targets a protein researchers have called a 'greasy ball' — a reference to KRAS's historically intractable structure.
- The results were explicitly described as 'practice-changing,' a term with specific clinical weight implying a shift in standard-of-care thinking.
- The source excerpt provides no efficacy numbers — no response rate, PFS, OS, or comparator arm — making independent verification of the 'practice-changing' claim impossible from this source alone.
- It is unclear whether the data come from a randomized controlled trial or a single-arm study; the latter is prone to historical-control bias in pancreatic cancer.
- The 'practice-changing' framing originates from conference buzz, not yet a peer-reviewed publication or regulatory filing.
The ASCO presentation is a real, high-profile event and the KRAS targeting challenge is well-established, but the source lacks the numerical data needed to fully validate the claim.
Calling results 'practice-changing' without disclosed endpoints or a comparator arm is a meaningful overclaim risk; the source itself acknowledges this is 'much-awaited,' signaling high prior expectation that can color interpretation.
If the claim holds, this addresses a mutation present in ~90% of pancreatic cancers — one of oncology's most lethal and treatment-resistant diseases — making the potential impact genuinely large.
- 1 source on file
- Avg trust 80/100
- Trust 80/100
Time horizon
Community read
Glossary
- GTPase domain
- A functional region of a protein that binds and hydrolyzes GTP (guanosine triphosphate), a molecule that provides energy for cellular processes. In KRAS, this domain is responsible for its activity as a molecular switch.
- GTP-bound state
- The active configuration of a protein when it has bound to GTP, allowing it to transmit cellular signals. This is distinct from the inactive GDP-bound state.
- Progression-free survival (PFS)
- A clinical measure of how long a patient survives without their cancer worsening or progressing. It is commonly used as an endpoint in cancer trials to assess treatment effectiveness.
- Randomized controlled trial
- A rigorous clinical study design where patients are randomly assigned to receive either a new treatment or a standard treatment (control), allowing for unbiased comparison of effectiveness.
- Breakthrough Therapy designation
- An FDA classification given to drugs that show substantial improvement over existing treatments for serious conditions, which expedites their review and approval process.
- Pancreatic ductal adenocarcinoma
- The most common type of pancreatic cancer, originating in the cells lining the ducts that carry digestive enzymes in the pancreas.
What's your read?
Your read shapes future topic weighting.
Your vote feeds topic weights, community direction and future prioritisation. Open community direction
Sources
Optional Submit a prediction Optional: add your prediction on the core question if you like.
Prediction
Will Revolution Medicines' KRAS inhibitor receive FDA approval for pancreatic cancer within the next 24 months?